Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans

• Main Authors: Jin-Woo Park (Author), Jong-Min Kim (Author), Ji Hyeon Noh (Author), Kyoung-Ah Kim (Author), Hyewon Chung (Author), EunJi Kim (Author), Minja Kang (Author), Ji-Young Park (Author)
• Format: Book
• Published: MDPI AG, 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Dapagliflozin, a selective sodium-glucose co-transporter-2 inhibitor, and linagliptin, a competitive, reversible dipeptidyl peptidase-4 inhibitor, are commonly prescribed antidiabetic medications in general clinics. Since there are several merits to combining them in a fixed-dose combination product...